GlassScriptPhysician profile
Muhammad A Hamadeh
NPI 1902860083
$20,903.90
in general payments reported to CMS, 2019-2025
40 companies · $1,955 in 2025
The $1,955 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,664 · 2020: $628 · 2021: $2,039 · 2022: $2,865 · 2023: $1,166 · 2024: $2,587 · 2025: $1,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,518 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,517.98 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,039.40 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Amag Pharmaceuticals, INC. | $4,037.35 | 2019 | |
| Mylan Institutional INC. | $4,031.55 | 2019 | |
| Glaxosmithkline, LLC. | $1,871.04 | 2019-2025 | Nucala, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $929.37 | 2019-2024 | Xywav |
| Boehringer Ingelheim Pharmaceuticals, INC. | $630.92 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Inspire Medical Systems, INC. | $432.53 | 2021-2025 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $399.71 | 2023-2025 | Lumryz |
| Electromed, INC. | $346.60 | 2022-2025 | Smartvest |
| Genzyme Corporation | $343.72 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $233.11 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $232.71 | 2022-2025 | Dupixent |
| Insmed, INC. | $230.66 | 2023-2025 | Arikayce, Brinsupri |
| Pulmonx Corporation | $211.78 | 2023-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Mallinckrodt Hospital Products INC. | $198.95 | 2020-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $193.11 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $192.68 | 2019-2023 | Xolair |
| Actelion Pharmaceuticals US, INC. | $185.46 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Philips North America LLC | $158.64 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.43 | 2023-2025 | Glassia, Fruzaqla |
| Merck Sharp & Dohme LLC | $127.10 | 2019-2023 | Dificid, Zerbaxa |
| Amgen INC. | $112.01 | 2023-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $107.85 | 2019-2025 | |
| Astellas Pharma US INC | $70.92 | 2024-2025 | Xtandi, Vyloy |
| Mallinckrodt Enterprises LLC | $51.65 | 2019 | |
| Sunovion Pharmaceuticals INC. | $50.74 | 2019 | |
| Karyopharm Therapeutics INC. | $48.94 | 2023-2025 | Xpovio |
| Celgene Corporation | $47.47 | 2023 | |
| Progenics Pharmaceuticals, INC. | $34.08 | 2023 | Pylarify |
| Mylan Specialty L.P. | $32.17 | 2019-2021 | |
| Baxter Healthcare | $28.15 | 2022 | |
| Advanced Respiratory, INC | $26.99 | 2021 | |
| Inogen, INC. | $21.67 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Resmed Corp | $20.20 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $18.59 | 2022 | |
| Circassia INC. | $15.49 | 2019 | |
| Pfizer INC. | $15.39 | 2025 | |
| Agios Pharmaceuticals, INC. | $15.19 | 2024 | Pyrukynd |
| Lilly USA, LLC | $14.34 | 2025 | Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.24 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Hamadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.